Serum levels of galectin-9 in patients with oral squamous cell carcinoma


Aim: Understanding the process of tumor cell proliferation and metastasis will have a substantial influence on management of the aggressive oral squamous cell carcinoma (OSCC).The role of galectin-9 is well-known in several aspects of cancer progression, such as apoptosis, cell adhesion and immune system responses. The aim of the present study was to investigate whether the serum levels of galectin-9 play a significant role in the pathogenesis of OSCC. Method and material: This was a cross sectional study. The data were obtained from 60 patients with histological confirmed OSCC who had medical document in Khalili hospital, Shiraz, Iran, and 28 healthy donors as control group who refer to Blood Transfusion Center, Shiraz, Iran. The levels of galectin-9 were measured by Elisa sandwich assay, following the manufacturer’s protocol. Student t test was used to identify significant difference between two groups according to age, sex and serum levels of galectin-9.To evaluate association between location and grade of tumor lesions with the levels of galectin-9, one way ANOVA was used. Results: The mean levels of galectin-9 in patients with OSCC (6.42± 2.08) were less than control subjects (6.65 ± 2.05), while there is not any significant difference between them (P value=0.0564).we did not find any significant relation between stage, grade and location of tumor lesions with the serum levels of galectin-9. Conclusion: Serum levels of galectin-9 do not seem to play any significant role in the pathogenesis of oral squamous cell carcinoma.


  • Abagale SA, Atiemo S, Abagale FK, Ampofo A, Amoah CY, Aguree S, Osei Y (2019) Pesticide Residues Detected in Selected Crops, Fish and Soil from Irrigation Sites in the Upper East Region of Ghana.
  • Akhter M, Hossain S, Rahman QB, Molla MR (2011) A study on histological grading of oral squamous cell carcinoma and its co-relationship with regional metastasis. Journal of oral and maxillofacial pathology: JOMFP 15(2): 168.
  • Andisheh Tadbir A, Fattahi MJ, Khademi B, Pourshahidi S, Ebrahimi H, Sardari Y, Fattah Z. (2010) Serum Level of Galectin-3 in Patients with Oral Squamous Cell Carcinoma. Middle East Journal of Cancer 1(2): 77-81.
  • Anneroth G, Batsakis J, Luna M (1987) Review of the literature and a recommended system of malignancy grading in oral squamous cell carcinomas. European Journal of Oral Sciences 95(3): 229-49.
  • Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S, Raymond E, Faivre S (2014) Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer treatment reviews 1;40(2): 307-19.
  • Boonkitticharoen V, Kulapaditharom B, Leopairut J, Kraiphibul P, Larbcharoensub N, Cheewaruangroj W, Chintrakarn C, Pochanukul L (2008) Vascular endothelial growth factor A and proliferation marker in prediction of lymph node metastasis in oral and pharyngeal squamous cell carcinoma. Archives of Otolaryngology–Head & Neck Surgery 134(12): 1305-11.
  • Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A, Kirchner T (2005) Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and β-catenin. Cells tissues organs 179(1-2): 56-65.
  • Chang SW, Kallarakkal TG, Abraham MT (2014) Changed expression of E-cadherin and galectin-9 in oral squamous cell carcinomas but lack of potential as prognostic markers. Asian Pacific Journal of Cancer Prevention 15(5): 2145-52.
  • Chang WA, Tsai MJ, Kuo PL, Hung JY (2017) Role of galectins in lung cancer. Oncology letters 14(5): 5077-5084.
  • Choi SI, Seo KW, Kook MC, Kim CG, Kim YW, Cho SJ (2017) Prognostic value of tumoral expression of galectin-9 in gastric cancer. Turk J Gastroenterol 28: 166-170.
  • Dar AA, Dwivedi AK, Iyer PK, Khan A (2018) Indole derived “turn-on” fluorometric probe for dual detection of Hg2+ and Cu2+ ions at nanomolar level. Asian Journal of Green Chemistry 2(3. pp. 171-280): 171-180.
  • Fujita K, Iwama H, Oura K, Tadokoro T, Samukawa E, Sakamoto T, Nomura T, Tani J, Yoneyama H, Morishita A, Himoto T (2017) Cancer therapy due to apoptosis: Galectin-9. International journal of molecular sciences 1;18(1): 74.
  • Ghantous Y, Abu IE (2017) Global incidence and risk factors of oral cancer. Harefuah 156(10): 645-9.
  • Heusschen R, Griffioen AW, Thijssen VL (2013) Galectin-9 in tumor biology: a jack of multiple trades. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1836(1): 177-85.
  • Hossaka TA, Ribeiro DA, Focchi G, André S, Fernandes M, Carapeto FC, Silva MS, Oshima CT (2014) Expression of Galectins 1, 3 and 9 in normal oral epithelium, oral squamous papilloma, and oral squamous cell carcinoma. Dental research journal 11(4): 508.
  • Hossaka TA, Ribeiro DA, Focchi G, André S, Fernandes M, Carapeto FC, Silva MS, Oshima CT (2014) Expression of Galectins 1, 3 and 9 in normal oral epithelium, oral squamous papilloma, and oral squamous cell carcinoma. Dental research journal 11(4): 508.
  • Hughes RC (2001) Galectins as modulators of cell adhesion. Biochimie 83(7): 667-76.
  • Irie A, Yamauchi A, Kontani K, Kihara M, Liu D, Shirato Y, Seki M, Nishi N, Nakamura T, Yokomise H, Hirashima M (2005) Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clinical Cancer Research 11(8): 2962-8.
  • Irie A, Yamauchi A, Kontani K, Kihara M, Liu D, Shirato Y, Seki M, Nishi N, Nakamura T, Yokomise H, Hirashima M (2005) Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clinical Cancer Research 11(8): 2962-8.
  • Jadhav KB, Gupta N (2013) Clinicopathological prognostic implicators of oral squamous cell carcinoma: need to understand and revise. North American journal of medical sciences 5(12): 671.
  • Jiang J, Jin MS, Kong F, Cao D, Ma HX, Jia Z, Wang YP, Suo J, Cao X (2013) Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer. PLoS One 8:e81799.
  • John S, Mishra R (2016) Galectin-9: from cell biology to complex disease dynamics. Journal of biosciences 41(3): 507-34.
  • Kacimi R, Khouzami K, Abram T, Bejjit L, Bennani MN, Bouachrine M (2020) Electro-Optical and Photovoltaic Properties of Oligothiophene and Derivatives; Experimental and Theoretical Investigations. Chemical Methodologies 4(2. pp. 115-219): 203-219.
  • Kageshita T, Kashio Y, Yamauchi A, Seki M, Abedin MJ, Nishi N, Shoji H, Nakamura T, Ono T, Hirashima M (2002) Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer 99: 809-816.
  • Kasamatsu A, Uzawa K, Nakashima D, Koike H, Shiiba M, Bukawa H, Yokoe H, Tanzawa H (2005) Galectin-9 as a regulator of cellular adhesion in human oral squamous cell carcinoma cell lines. International journal of molecular medicine 16(2): 269-73.
  • Klibi J, Niki T, Riedel A, Pioche-Durieu C, Souquere S, Rubinstein E, Le Moulec S, Guigay J, Hirashima M, Guemira F, Adhikary D (2009) Blood diffusion and Th1-suppressive effects of galectin-9–containing exosomes released by Epstein-Barr virus–infected nasopharyngeal carcinoma cells. Blood 113(9): 1957-66.
  • Kobayashi T, Kuroda J, Ashihara E, Oomizu S, Terui Y, Taniyama A, Adachi S, Takagi T, Yamamoto M, Sasaki N, Horiike S (2010) Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways. Leukemia 24(4): 843.
  • Lahm H, André S, Hoeflich A, Fischer JR, Sordat B, Kaltner H, Wolf E, Gabius HJ (2001) Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. Journal of cancer research and clinical oncology 127(6): 375-86.
  • Le Campion AC, Ribeiro CM, Luiz RR, da Silva Júnior FF, Barros HC, dos Santos KD, Ferreira SJ, Gonçalves LS, Ferreira SM (2017) Low survival rates of oral and oropharyngeal squamous cell carcinoma. International journal of dentistry.
  • Liang M, Ueno M, Oomizu S, Arikawa T, Shinonaga R, Zhang S, Yamauchi A, Hirashima M (2008) Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma. Journal of cancer research and clinical oncology 134(8): 899-907.
  • Noguti J, De Moura CF, De Jesus GP, Da Silva VH, Hossaka TA, Oshima CT, Ribeiro DA (2012) Metastasis from oral cancer: an overview. Cancer Genomics-Proteomics 9(5): 329-35.
  • Pires FR, Ramos AB, Oliveira JB, Tavares AS, Luz PS, Santos TC (2013) Oral squamous cell carcinoma: clinicopathological features from 346 cases from a single oral pathology service during an 8-year period. Journal of Applied Oral Science 21(5): 460-7.
  • Sabatos CA, Chakravarti S, Cha E, Schubart A, Sanchez-Fueyo A, Zheng XX, Coyle AJ, Strom TB, Freeman GJ, Kuchroo VK (2003) Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol 4: 1102-1110.
  • Sanchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, Sabatos CA, Manlongat N, Bender O, Kamradt T, Kuchroo VK, Gutierrez-Ramos JC, Coyle AJ, Strom TB (2003) Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol 4: 1093-1101.
  • Sato M, Nishi N, Shoji H, Seki M, Hashidate T, Hirabayashi J, Kasai KI, Hata Y, Suzuki S, Hirashima M, Nakamura T (2002) Functional analysis of the carbohydrate recognition domains and a linker peptide of galectin-9 as to eosinophil chemoattractant activity. Glycobiology 12(3): 191-7.
  • Serkova, E. I., Voronin, A. M., Salankova, S. Y., Bychkova, N. V., Klyuikov, V. V., & Savin, A. V. (2019). Design-Oriented Education Environment as a Means of Improving the Quality of Undergraduate Education in Terms of the Competency-Based Approach. Journal of Environmental Treatment Techniques, 7(4), 601-612.
  • Türeci Ö, Schmitt H, Fadle N, Pfreundschuh M, Sahin U (1997) Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin’s disease. Journal of Biological Chemistry 272(10): 6416-22.
  • Vladoiu MC, Labrie M, St-Pierre Y (2014) Intracellular galectins in cancer cells: potential new targets for therapy. International journal of oncology 1;44(4): 1001-14.
  • Weber M, Büttner-Herold M, Distel L, Ries J, Moebius P, Preidl R, Geppert CI, Neukam FW, Wehrhan F (2017) Galectin 3 expression in primary oral squamous cell carcinomas. BMC cancer 17(1): 906
  • Wedemeyer J, Vosskuhl K (2008) Role of gastrointestinal eosinophils in inflammatory bowel disease and intestinal tumours. Best Practice & Research Clinical Gastroenterology 22(3): 537-49.
  • Xu XC, El-Naggar AK, Lotan R (1995) Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. The American journal of pathology 147(3): 815
  • Yang J, Zhu L, Cai Y, Suo J, Jin J (2014) Role of downregulation of galectin-9 in the tumorigenesis of gastric cancer. International journal of oncology 45(3): 1313-20.
  • Yang RY, Rabinovich GA, Liu FT (2008) Galectins: structure, function and therapeutic potential. Expert reviews in molecular medicine 10.
  • Zhang F, Zheng M, Qu Y, Li J, Ji J, Feng B, Lu A, Li J, Wang M, Liu B (2009) Different roles of galectin-9 isoforms in modulating E-selectin expression and adhesion function in LoVo colon carcinoma cells. Molecular biology reports 36(5): 823-30.
  • Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6: 1245-1252.


This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.